Navamedic Finalizes Acquisition of DNE Pharma Business

Navamedic ASA has officially completed its acquisition of DNE Pharma’s business, marking a major milestone in the company’s strategic expansion into the addiction treatment market. The transaction includes DNE Pharma’s full product portfolio, key employees, intellectual property, licenses, and distribution agreements.

Among the acquired assets are notable therapies such as Ventizolve, a nasal spray for opioid overdose reversal, and Levopidon and Metadon Dne, both used in opioid substitution therapy. The portfolio will be integrated into Navamedic’s commercial platform to support rapid market entry and geographic expansion across the Nordics and select European regions.

“This acquisition represents a significant step in our strategic expansion into the rapidly growing field of addiction treatment and is well aligned with our long-term growth ambitions,” said Navamedic CEO Kathrine Gamborg Andreassen. She also expressed appreciation for the support of shareholders and partners involved in the transaction, which was unanimously backed in a general meeting held on July 14.

The acquisition was financed through a NOK 110 million loan from Nordea Bank and a recently approved rights issue. Navamedic received advisory and legal support from DNB Carnegie, Nordea Corporate Finance, and law firm Thommessen to complete the deal.

Geir Ove Engeset, CEO of DNE Pharma, welcomed the agreement, stating, “We are very pleased closing this transaction with Navamedic and confident that their team will continue to grow the opioid substitution business developed by DNE Pharma, particularly the Ventizolve products.”

The integration of DNE Pharma’s business is expected to enhance Navamedic’s position in the specialty pharma space and accelerate its efforts to address the public health challenge of opioid addiction.